- Book
- November 2016
- 330 Pages
- Report
- March 2025
- 368 Pages
Global
From €2447EUR$2,655USD£2,062GBP
- Report
- October 2026
- 245 Pages
Global
From €3848EUR$4,175USD£3,242GBP
- Report
- October 2026
- 367 Pages
Global
From €3848EUR$4,175USD£3,242GBP
- Report
- October 2026
- 326 Pages
Global
From €3848EUR$4,175USD£3,242GBP
- Report
- September 2026
- 321 Pages
Global
From €3848EUR$4,175USD£3,242GBP
- Report
- September 2026
- 310 Pages
Asia Pacific
From €3848EUR$4,175USD£3,242GBP
- Report
- September 2026
- 310 Pages
Global
From €3848EUR$4,175USD£3,242GBP
- Report
- September 2026
- 90 Pages
From €4378EUR$4,750USD£3,688GBP
- Report
- August 2026
- 90 Pages
From €4378EUR$4,750USD£3,688GBP

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy.
The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more